The Cancer Genome Atlas(TCGA) data show that PDGFRA mutations and amplifications are also common in malignant tumors, such as glioblastoma [21], melanoma [22, 23], non-small cell lung cancer [24], and hematologic malignancies [25]. This evidence concerns the gene PDGFRA and non-small cell lung carcinoma.